Association between trace elements and preeclampsia: A retrospective cohort study.

BACKGROUND: Preeclampsia is the main cause of maternal and perinatal death. Multiple studies suggest that trace elements were associated with preeclampsia, but the results varied, and less known about early or mid-term pregnancy of trace elements and preeclampsia. We aim to explore the association between mid-term pregnancy trace elements levels and preeclampsia. METHODS: The retrospective cohort study was consecutively conducted in Foshan Fosun Chancheng Hospital, Guangdong Province, China, from August 1, 2019, to November 30, 2019. Trace elements are derived from the laboratory data system, measured in maternal whole blood during 12-27 (+6) weeks of pregnancy by flame atomic absorption spectrometer method. Preeclampsia diagnosis and covariance were ascertained from the electronic medical records system. We used multivariable logical regression to estimate odds ratios (OR) and 95% CIs. RESULTS: A total of 2186 participants were included in this study, and 59 (2.70%) women developed preeclampsia. After multivariable adjustment, the OR of Mg levels for preeclampsia was 0.35 (95%CI:0.06,2.20). The fifth quintiles of Mg were associated with 0.29 (95% CI：0.10,0.85) times lower risk of preeclampsia compared with the first quintile, with a dose-response trend (P for trend = 0.056). Per 1 µmol/L increment in Cu was associated with 11% lower risk of preeclampsia (OR=0.89; 95% CI, 0.78,1.02). Compared with the first quintile, the second, third，fourth，fifth quintile of Cu was associated with a odd ratio of 0.12 (95% CI:0.03,0.43),0.67 (95% CI:0.30,1.48),0.33 (95% CI:0.15,0.76) and 0.26 (95% CI:0.10,0.66),respectively. Null associations were observed for Zn, Fe, Ca. CONCLUSIONS: Higher blood Mg and Cu levels in mid-term pregnancy were associated with lower preeclampsia risk.

Association of blood lead levels with preeclampsia: A cohort study in China.

BACKGROUND: Preeclampsia is the main cause of maternal and perinatal death, especially in developing countries. Multiple studies suggest that blood lead levels in pregnancy are a risk factor for preeclampsia, even with low levels of blood lead. But less knows the dose-effect relationship of preeclampsia in low blood lead levels. OBJECTIVES: This study aims to assess the association between blood lead levels and preeclampsia and to explore its dose-effect relationship between low blood lead levels and preeclampsia. METHODS: The retrospective cohort study was consecutively conducted in a comprehensive tertiary hospital in Foshan city of Guangdong Province, China, from August 1, 2019, to November 30, 2019. Blood lead levels were measured in maternal whole blood in 12-27 (+6) weeks of pregnancy, using atomic absorption spectrometer. Preeclampsia diagnosis was ascertained from the electronic medical records system. The risk of preeclampsia was estimated by multivariable logical regression analysis, and a two-stage linear regression model was established to find out the dose-effect. RESULTS: A total of 2174 people were included in this study, and 59 (2.7%) women developed preeclampsia. The dose-effect analysis revealed a non-linear association between blood lead levels and the risk of preeclampsia, with a cut-off point at 4.2 µg/dl. When blood lead levels were over 4.2 µg/dl, the risk of preeclampsia increased significantly with an increase in blood lead levels (OR = 2.05, 95%CI: 1.50, 2.81). In the multivariate regression models, per 1 µg/dl increment in blood lead levels was associated with 43% higher risk of developing preeclampsia (OR = 1.43,95%CI:1.17,1.74). Moreover, the association between blood lead levels and preeclampsia was stable in different subgroups. CONCLUSIONS: Low levels of lead exposure had a dose-effect relationship of preeclampsia, with a cut-off point at 4.2 µg/dl. Blood lead levels had a non-linear association with preeclampsia. When the blood lead levels were higher than 4.2 µg/dl, the risk of preeclampsia increases by 105% for every 1 µg/dl increase in blood lead levels.

Endometrial clear cell carcinoma invading the right oviduct with a cooccurring ipsilateral oviduct adenomatoid tumor: A case report.

BACKGROUND: To investigate the clinicopathological features of endometrial clear cell carcinoma that has invaded the right oviduct with a cooccurring ipsilateral oviduct adenomatoid tumor. CASE SUMMARY: A case of endometrial clear cell carcinoma invading the right oviduct with a cooccurring ipsilateral oviduct adenomatoid tumor was collected and analyzed using pathomorphology and immunohistochemistry. Endometrial clear cell carcinoma cells were distributed in a solid nest, papillary, shoe nail-like, and glandular tube-like distribution. There was infiltrative growth, and tumor cells had clear cytoplasm and obvious nuclear heteromorphism. The cancer tissue was necrotic and mitotic. The cancer tissue invaded the right oviduct. The ipsilateral oviduct also had an adenomatoid tumor. The adenomatoid tumor was arranged in microcapsules lined with flat or cubic cells that were surrounded by smooth muscle tissue. The adenomatoid tumor cells were round in shape. CONCLUSION: Clear cell carcinoma of the endometrium can invade the oviduct and occur simultaneously with tubal adenomatoid tumors. Upon pathological diagnosis, one should pay close attention to distinguishing whether an endometrial clear cell carcinoma is invading the oviduct or whether it is accompanied by an adenomatoid tumor of the oviduct. Immunohistochemistry is helpful to differentiate these two disease entities. Endometrial clear cell carcinomas express Napsin-A and P16 and are negative for estrogen receptor and progesterone receptor. The presence of endometrial clear cell carcinoma does not affect the expression of CK and calretinin in adenomatoid tumors.

The Prognostic Values Of Circulating Tumor Cells In Lung Carcinoma: An Analysis On 98 Chinese Patients.

AIM: To examine the prognostic values of circulating tumor cells (CTCs) in patients with advanced lung cancer. PATIENTS AND METHODS: A total of 98 patients with their CTCs enumerated in 2017 was recruited. Data were retrieved from medical records for comparison. Patients' overall survival (OS) and progression-free survival (PFS) were studied using Kaplan-Meier curve with log rank test. RESULTS: Seventy-three percent of the patients were male, and nearly half of the patients (44.8%) were smokers. Most tumors were adenocarcinoma (73.4%), and about 60% of the cases were diagnosed at stage IV. Half of the patients showing less than nine CTCs. Patients' OS were significantly associated with total CTC count (P=0.047), epithelial CTC count (P=0.027), mixed CTC count (P=0.004), and use of adjuvant chemotherapy (P=0.001). For PFS, it was strongly associated with tumor backgrounds (T stage, P=0.002; M stage, P=0.001; TMN stage, P<0.001), cancer biomarkers (CEA, P=0.004; CA125, P=0.004; CA153, P=0.045), and treatment strategy (surgical intervention, P=0.025; first-line chemotherapy, P<0.001). CONCLUSION: The present study clearly indicated the significant associations between CTC and overall survival of patients with lung cancer.